Lv1
30 积分 2023-02-18 加入
The Affinity Advantage
18天前
已完结
Histological healing: should it be considered as a new outcome for ulcerative colitis? Expert Opin Biol Ther. 2020 Apr;20(4):407-412
29天前
已完结
Short- and Long-Term Outcomes of Mirikizumab for Ulcerative Colitis: A Real-World Multicenter Retrospective Cohort Study from the INSIGHT study
1个月前
已关闭
Comparative Effectiveness and Safety of Upadacitinib vs Risankizumab for Ulcerative Colitis
1个月前
已关闭
Therapeutic Efficacy of Risankizumab for Small Intestinal Lesions in Crohn's Disease: A Retrospective Study Using Double-Balloon Endoscopy
2个月前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
2个月前
已完结
Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence
2个月前
已完结
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
3个月前
已完结
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study
3个月前
已完结
Beyond tumor necrosis factor and interleukin-12/23: The rise of interleukin-23 inhibitors in inflammatory bowel disease management
3个月前
已关闭
皖公网安备34019202002308
